William Daly - Senior Vice President- Business Development
Mr. Daly joined Akebia from Halozyme Therapeutics, where he was the Head of Business Development and Alliance Management.
Prior to Halozyme, Mr. Daly was Senior Vice President – Business Development at Cougar Biotechnology. At Cougar, Mr. Daly was responsible for the acquisition of Cougar by Johnson & Johnson for $1 billion. Following the acquisition, Mr. Daly co-led the integration of Cougar and J&J and was also Site Head of the Los Angeles facility, which was conducting two phase 3 trials of the prostate cancer drug, abiraterone acetate (subsequently approved and launched as Zytiga®).
Prior to joining Cougar, Mr. Daly held a number of business development and senior executive positions over the past ten years at Allergan, Chiron and Novartis as well as a number of start-up biotechnology companies. Before moving into industry, Mr. Daly was an investment banker for nine years, most recently served as a Managing Director for Prudential Vector Healthcare Group.
Prior to becoming an investment banker, Mr. Daly practiced corporate and securities law for ten years. He worked at Morgan, Lewis & Bockius and was a partner in a boutique securities firm in Los Angeles. Mr. Daly graduated from UC Berkeley with a degree in biochemistry and earned his law degree and his MBA from UCLA.